Five-year period evaluation of isolated agents and their resistance profiles in intensive care unit patients with malignancy

Duygu Mert¹, Selda Muslu², Alparslan Merdin³, Arif Timuroğlu², Ece Dirim⁴, Süheyla Ünver², Mustafa Ertek¹

¹ Infectious Diseases and Clinical Microbiology Clinic, University of Health Sciences Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey
² Anesthesia and Reanimation Intensive Care Unit, University of Health Sciences Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey
³ Hematology Clinic and Bone Marrow Transplantation Unit, University of Health Sciences Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey
⁴ Medical Microbiology Laboratory, University of Health Sciences Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey

Abstract

Introduction: Patients treated in the intensive care unit (ICU) are usually patients who deteriorated health condition and could have longer hospital stay compared to other patients. Hospital infections are more common in ICU patients [1]. Such patients might also have frequently administered invasive interventions and might be under broad-spectrum antibiotherapy [1]. Nosocomial infections are more common in the ICU patients [2]. These patients were hospitalized many times before the ICU and often had a history of broad-spectrum antibiotic use. Infections with extensively drug-resistant, multidrug-resistant and pandrug-resistant microorganisms are common [3]. It would be useful to know the bacteria isolated in the ICU and their antibiotic resistance profiles and to review the use of antibiotics in the light of these data.

The aim of this study was to evaluate all microorganisms and treatment resistance profiles isolated from clinical specimens sent for hospital infections in the ICU with hematologic malignancies, solid organ tumors or other underlying diseases in a tertiary care hospital between January 1, 2014 and December 31, 2018. In addition, to determine the epidemiological characteristics, risk factors, changes in the distribution and frequency of isolated bacteria. In addition, to review the antimicrobial resistance status of bacteria. For this reason, we think that this study will be
useful in determining the antibiotics policies of the country.

Methodology

This is a retrospective study. Approval was obtained from the Ethics Committee of University of Health Sciences Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital (Approval date: 03/20/2019 and decision no: 2019-03/235).

Patients who were hospitalized in the ICU between January 1, 2014 and December 31, 2018 and had blood samples/other cultures taken for high fever were included in the study.

At least two bottles of blood cultures were taken at 30 minutes intervals for each patient when the fever was ≥ 38.2°C. Blood cultures were obtained from different peripheral veins, one other also from the catheter, and another from the patients with central venous catheter (CVC). Automated BacT/ALERT 3D (bioMerieux, Marcy-l’Etoile, France) system was used to detect growth in blood cultures. Antibiotic susceptibility tests were performed by using VITEK 2 (bioMerieux, Marcy-l’Etoile, France) AST (Antimicrobial susceptibility testing) cards. Patients were divided into bloodstream infections in accordance with the definitions of Centers for Disease Control and Prevention (CDC).

Clinical specimens were seeded on eosine methylene blue agar, blood agar and Sabouraud dextrose agar. Respiratory tract samples consisted of bronchoalveolar lavage, sputum and/or tracheal aspirate. All samples were evaluated for the presence of leukocytes and bacteria by Gram staining. For Gram-positive bacteria, positive culture properties on the plaque, Gram staining, catalase, coagulase tests and VITEK 2 ID (bioMerieux, Marcy-l’Etoile, France) cards were used. In the identification of Gram-negative isolates, culture positivity/negativity characteristics, Gram stain, oxidase test and VITEK 2 ID cards were used. VITEK 2 AST (bioMerieux, Marcy-l’Etoile, France) cards were used to detect antibiotic susceptibility of growing microorganisms. Disc diffusion test was performed by using Becton Dickinson (Becton, Dickinson and Company, Towson, MD, USA) and Oxoid antimicrobial discs (Oxoid Limited, Hampshire, UK) according to Kirby-Bauer disc diffusion susceptibility test protocol, inoculation of the Muller Hinton agar plate. VITEK 2 AST were used to detect expanded spectrum beta lactamase in Gram-negative bacteremia.

After detecting the causative agents together with the current diagnoses, the other results of the patients were obtained from the patient records in the electronic environment. Patients were divided into three groups as those with hematological malignancies, those with solid organ tumors and those with other underlying diseases.

The demographic data, underlying disease, focus of infections, culture positive strains and antibiogram results were recorded on a previously prepared form.

Patients aged 18 years or older, patients who were hospitalized in the anesthesia intensive care unit and patients who were diagnosed with infection by clinically, laboratory tests and/or microbiologically were included in the study. Patients under the age of eighteen and patients who were pregnant were excluded from the study.

Statistical analysis

SPSS (IBM SPSS Statistics 24) was used to compare the statistical data. The data were entered into the statistical package program and analyzed using the same package program. Frequency tables and descriptive statistics were used to interpret the findings.

Descriptive data were presented as categorical frequency distribution and percentage (%) and measured as mean ± standard deviation (SD) and median (maximum, smallest values).

Cross Tab with Chi-Square test was used to examine the relationship between two qualitative variables. P<0.05 was considered as statistically significant.

Results

The number of patients in the ICU was 1388 and the number of patients whose culture was found to be positive was 351. In 547 total clinical samples, culture positivity was detected as a result of nosocomial infection.

The mean age of the patients was 66 and the age range was between 18 and 100 years old. 53.5% of the patients were female and 46.5% were male.

Culture positivity was detected in 96 (17.5%) patients with hematological malignancies in the ICU, 207 (38%) patients with solid organ tumors, and 244 (44.5%) patients with other underlying diseases (Table 1).

Deep tracheal aspirate culture (157) was the most culture positivity seen test and it was followed by urine culture (108), peripheral blood culture (95), and bronchoalveolar lavage culture (82), respectively. Eighty Gram-positive bacteria, 389 Gram-negative bacteria and 78 fungi infection were identified in a total of 547 positive cultures (Table 1).
Table 1. Distribution of growth factors by disease groups.

|                         | Patients with hematologic malignancies | Patients with solid organ tumors | Patients with other underlying diseases |
|-------------------------|----------------------------------------|----------------------------------|----------------------------------------|
| Reproduction number, n (%) | 96 (17.5%)                             | 207 (38%)                        | 244 (44.5%)                           |
| Gram-positive bacteria, n (%) | 12 (12.5%)                             | 28 (13.5%)                      | 40 (16.1%)                            |
| Gram-negative bacteria, n (%) | 76 (79.2%)                             | 143 (69.1%)                     | 170 (69.8%)                           |
| Fungus, n (%)              | 8 (8.3%)                               | 36 (17.4%)                      | 34 (14.6%)                            |

Table 2. Distribution of growth factors by years.

|                         | 2014     | 2015    | 2016    | 2017    | 2018    | Total   |
|-------------------------|----------|---------|---------|---------|---------|---------|
| Gram-positive bacteria, n (%) | 4 (3.7)  | 14 (11) | 12 (11.1) | 1 (1.3) | 43 (7.9) |
| S. aureus and CoNS     | 1 (0.9)  | 1 (0.9) | -       | -       | 5 (0.9)  |
| E. faecalis and E. faecium | 5 (4.7)  | 4 (3.1) | 6 (5.6) | 8 (10.7) | 28 (5.1) |
| Other Gram-positive bacteria | 1 (0.9)  | 2 (1.6) | -       | -       | 4 (0.7)  |
| Gram-negative bacteria, n (%) | 11 (10.2) | 20 (5.8) | 19 (17.6) | 9 (12) | 80 (14.5) |
| E. coli                | 4 (3.7)  | 14 (11) | 12 (11.1) | 1 (1.3) | 43 (7.9) |
| Acinetobacter spp.     | 1 (0.9)  | 1 (0.8) | 2 (1.6) | -       | 4 (0.7)  |
| Klebsiella spp.        | 7 (6.5)  | 13 (10.2) | 10 (9.3) | 8 (10.7) | 49 (9.0) |
| Pseudomonas spp.       | 14 (13.1) | 12 (9.4) | 9 (8.3) | 6 (8.0) | 52 (9.5) |
| S. marcescens          | 1 (0.9)  | 1 (0.8) | -       | 3 (4.0) | 6 (1.1)  |
| Proteus spp.           | 1 (0.9)  | 2 (1.5) | -       | 2 (1.9) | 7 (1.3)  |
| Enterobacter spp.      | 2 (1.9)  | 2 (1.6) | 1 (0.9) | 4 (5.3) | 10 (1.8) |
| Other Gram-negative bacteria | 2 (1.9)  | 6 (4.7) | 5 (4.6) | -       | 18 (3.3) |
| Fungus, n (%)          | 17 (15.9) | 18 (14.2) | 19 (17.6) | 3 (4.0) | 78 (14.3) |

Table 3. Resistance distribution of growth factors by years.

|                         | 2014     | 2015    | 2016    | 2017    | 2018    | Total   |
|-------------------------|----------|---------|---------|---------|---------|---------|
| MRSA                    | 2        | -       | 2       | -       | -       | 4       |
| VRE                     | 1        | 1       | 1       | 1       | 2       | 6       |
| MRCoNS                  | -        | 11      | 9       | 9       | 1       | 30      |
| Carbapenem resistance   | 55       | 61      | 58      | 43      | 41      | 258     |
| Colistin resistance     | 1        | 6       | 9       | 11      | 4       | 31      |
| ESBL                    | 1        | 12      | 7       | 11      | 3       | 44      |
| Total                   | 60       | 91      | 86      | 74      | 51      | 363     |
Gram-positive bacterial growth was found to be highest in patients with underlying disease, Gram-negative bacterial growth in hematological malignancies and fungal growth in patients with solid organ tumors, respectively (Table 1). Gram-negative bacteria were most frequently isolated in the cultures of patients in the ICU in between 2014 and 2018. This was followed by Gram-positive bacteria and fungus, respectively (Table 2).

Among the Gram-negative bacteria, Acinetobacter spp. was the most culture positive strain with the number of 223 (40.8%). It was followed by Pseudomonas spp. (n = 52) (9.5%) and Klebsiella spp. (n = 49) (9.0%). Thirty-one Acinetobacter spp. have been detected as colistin resistant. Carbapenem resistance was found in 258 of the Gram-negative bacteria and ESBL positivity was found in 44 of the Gram-negative bacteria strains. Resistance distribution of bacterial strains by years was shown in Table 3.

Four methicillin-resistant Staphylococcus aureus (MRSA), 6 vancomycin-resistant enterococci (VRE) and 30 methicillin-resistant coagulase-negative staphylococci (MRCoNS) were detected as resistant strains in Gram-positive bacteria (Table 3).

The highest multidrug resistance was found in the clinical materials of patients with other underlying diseases (45.7%). This resistance was most common in Acinetobacter spp., Klebsiella pneumoniae and Pseudomonas spp., respectively. Pandrug-resistant microorganisms was found mostly in the clinical material of patients with hematological malignancies (66.7%) (Table 4).

The highest fungal growth was found in patients with solid organ tumors (17.4%). This was followed by patients with other underlying diseases (14.6%) and patients with hematological malignancies (8.3%), respectively (Table 1). Candida albicans was the most detected by years. C. albicans was the most detected from all patients. This was followed by C. tropicalis and C. glabrata (Table 5).

No statistically significant difference was found between the disease groups in terms of any microorganism growth. There was no statistically significant difference between the disease groups in terms of multidrug resistance development.

**Discussion**

Identification of infections in the ICU is necessary in terms of treatment approach and determination of epidemiological characteristics [4]. Determining causative microorganisms and antibiotic susceptibilities is important in reducing morbidity and mortality as well as guiding empirical treatment [5].

In an international 1265 ICU study, 60% of patients are infected in during the study and infection is a strong and independent predictor of mortality (Odds ratio, 1.51; P<0.001) [6]. In general, and especially, the risks of infection with a resistant pathogen are increased

| Table 4. Distribution of multidrug-resistant and pandrug-resistant bacteria according to disease groups. |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|------------------|
| Patients with hematologic malignancies          | Patients with solid organ tumors                | Patients with other underlying diseases         |
| Multidrug-resistant*, n (%)                     | Multidrug-resistant*, n (%)                     | Multidrug-resistant*, n (%)                     |
| Acinetobacter spp.                              | Acinetobacter spp.                              | Acinetobacter spp.                              |
| 5 (14.3%)                                       | 14 (40.0%)                                     | 16 (45.7%)                                     |
| Klebsiella pneumoniae                          | 1                                            | 4                                            |
| Pseudomonas spp.                                | -                                            | -                                            |
| Pandrug-resistant*, n (%)                       | 2                                            | 1                                            |
| K. pneumoniae                                   | 2                                            | -                                            |
| § Multidrug-resistant microorganism as a result of carbapenem or colistin resistance; * Microorganism resistant to all antibiotics including carbapenem and colistin; Antibiotic distribution of multidrug-resistant microorganisms; In patients with hematologic malignancy: 4 Acinetobacter spp. were resistant to carbapenem and colistin, and 1 K. pneumoniae was resistant to all antibiotics except colistin; In patients with solid organ tumors: 10 Acinetobacter spp. were resistant to carbapenem and colistin, and 4 K. pneumoniae were resistant to all antibiotics except colistin; In patients with other underlying diseases: 8 Acinetobacter spp. carbapenem and colistin, 7 K. pneumoniae carbapenem, 1 Pseudomonas spp. were resistant to all antibiotics except colistin. |

| Table 5. Distribution of fungus according to disease groups. |
|------------------------------------------------------------|
| Fungus                                      | Patients with hematologic malignancies | Patients with solid organ tumors | Patients with other underlying diseases | Total, n |
|----------------------------------------------|---------------------------------------|----------------------------------|----------------------------------------|----------|
| Candida albicans                             | 4 (10.5)                              | 21 (55.3)                        | 13 (34.2)                              | 38       |
| Candida tropicalis                           | 0 (0.0)                               | 3 (30.0)                         | 7 (70.0)                               | 10       |
| Candida krusei                               | 3 (100.0)                             | 0 (0.0)                          | 0 (0.0)                                | 3        |
| Candida parapsilosis                         | 0 (0.0)                               | 4 (66.7)                         | 2 (33.3)                               | 6        |
| Candida lusitanica                           | 0 (0.0)                               | 0 (0.0)                          | 1 (100.0)                              | 1        |
| Candida glabrata                             | 0 (0.0)                               | 4 (50.0)                         | 4 (50.0)                               | 8        |
| Candida spp.                                 | 1 (8.3)                               | 4 (33.3)                         | 7 (58.3)                               | 12       |

921
with the length of stay in the ICU [7]. Compared with patients in the general hospital population, patients in the ICU have more chronic co-morbidities and more severe acute physiological disorders, so their immune system is relatively suppressed [7].

In this study, 547 of the clinical samples sent due to nosocomial infections in hospitalized patients in the ICU over a five-year period were detected. Of these culture positive patients, 96 (17.5%) had hematological malignancies, 207 (38%) had solid organ tumors and 244 (44.5%) had other underlying diseases.

MRSA, VRE, Acinetobacter baumannii and ESBL and/or carbapenemases positive Gram-negative bacteria and carbapenem-resistant Pseudomonas aeruginosa are increasingly isolated from patients in ICU [8]. Infections caused by these resistant pathogens are difficult to treat and these infections are associated with increased morbidity, mortality and cost [9].

In this study, 4 MRSA, 6 VRE and 30 MR CoNS were isolated from clinical samples of all three disease groups.

Comparison of reports from the National Health Care Network System and Centers for Disease Control and Prevention from 1999 to 2006 showed that the prevalence of multidrug-resistant pathogens in ICUs has been increasing in the United States [8].

The emergence of broad-spectrum resistance among gram-negative bacteria is particularly worrying as therapeutic options are scarce and sometimes no effective antimicrobial agents are available [10]. In our study, Gram-negative bacteria were the most isolated strain in clinical samples of all three patient groups.

Recently, colistin resistance has been increasing in Acinetobacter species and the increase in carbapenemase enzyme in Escherichia coli, Pseudomonas and Klebsiella species has increased resistance to carbapenems [8]. In our study, colistin resistance was 12.4% and carbapenem resistance was 75.8% in Acinetobacter species.

Some features increase the risk of infection with multidrug-resistant pathogens in ICUs, contributing to selective pressure and/or increased colonization pressure [11]. Infections caused by multidrug-resistant pathogens are associated with increased mortality, length of hospital stay, and hospital costs [12].

Patients with infections due to multidrug-resistant organisms are often at risk of chronic or acute disease and die from serious and complex underlying diseases [13]. Specifically, risk factors for resistant infections reported from ICUs are; aging, functional independence and/or decreased cognition, high severity of underlying concomitant conditions (eg diabetes, renal failure, malignancies, immunosuppression) and acute disease indices, including inter-institutional transfer, before admission to ICU prolonged hospital stay (especially in nursing homes), common situations in health settings (eg. hemodialysis units), frequent contact with healthcare professionals who simultaneously care for multiple patients who may serve as intermediaries for pathogen transfer between patients (shared equipment and contaminated environments) [13]. Presence of implanted devices such as central venous catheters, urinary catheters, and endotracheal tubes, bypassing natural host defense mechanisms and entry portals to pathogens, recent operations or other invasive procedures, receiving antimicrobial treatment before applying to the ICU create a selective environment leading to the emergence of multidrug-resistant bacteria [14].

In this study, Gram-negative bacteria were the most common agents in all three disease groups. The group with the highest Gram-negative bacterial growth was hematological malignancy group(79.2%). The reason for this was thought to be the long term immunosuppression due to both underlying disease and chemotherapy with the prior long term antibiotic use in this patient group.

ESBL-producing E. coli-related infections have become widespread in hospitals around the world [15]. A total of 44 ESBL-producing strains were also identified in our study.

The relationship between prior antibiotic usage and infections of drug-resistant organisms has been shown in several studies and in several methodologies [16]. In case-control studies, exposure to antibiotics has been consistently associated with the emergence of resistance to the same or a different class of antimicrobial agents [16]. In a study, antibiotic exposure was the most powerful single predictor for infections with drug-resistant Gram-negative pathogens [16].

Patients in the ICU are the highest risk group for Candida infections [17]. In addition to the risks associated with age, trauma, or burns, other factors include central venous catheters, total parenteral nutrition, broad-spectrum antibiotics, high APACHE score, acute renal failure, especially when requiring hemodialysis, surgery, especially abdominal surgery, gastrointestinal system perforations and are high risk factors [18]. In our study, fungus growth was detected in patients with solid organ tumors (17.4%). C. albicans was the most detected from patients with solid organ tumor. This was followed by C. glabrata and C. tropicalis. The reason for this was thought to be due to
the deterioration of organ integrity due to solid tumors, translocations and/or prior broad spectrum antibiotics used in these patients.

**Conclusion**

As a result, culture positive microorganisms in ICUs and their antibiotic resistance patterns may provide convenience in selecting appropriate empirical antibiotic therapy and antifungal therapy for patients. It may also help to protect patients from contamination with resistant microorganisms by following the standard measures of much more isolation and general hygiene.

**Acknowledgements**

The abstract of this research was presented as an oral presentation by the corresponding author at the congress “BUHASDER Kongresi 8. Tepecik Enfeksiyon Günleri” in October 2019, in İzmir, Turkey.

**Author’s contributions**

DM was the designer, coordinator, data collector and corresponding author. SM was the author, data collector and planner of study. The other authors were data collectors and authors.

**References**

1. Yilmaz N, Kose S, Agus N, Ece G, Akkoelu G, Kirakh C (2010) Microorganisms that grow in blood cultures, antibiotic susceptibility and nosocomial bateriaemia factors in intensive care unit patients. ANKEM 24:12-19.
2. Ok G, Gazi H, Tok D, Erbayan K (2007). Surveillance of hospital infections in Anesthesia Intensive Care Unit of Celal Bayar University. J Turk Soc Intens Care 7:452-457.
3. Bonnet V, Dupont H, Glorion S, Aupée M, Kipnis E, Gérard JL, Hanouz JL, Fischer MO (2019) Influence of bacterial resistance on mortality in intensive care units: a registry study from 2000 to 2013 (ICU Study). J Hosp Infect102:317-324.
4. Trilla A (1994) Epidemiology of nosocomial infections in adult intensive care units, Intensive Care Med 20 (Suppl 3):1-4.
5. Cetin ES, Aynalt A, Demirci S, Asci S, Arıdogan BC (2009) Factors of nosocomial infection isolated from patients hospitalized in neurology intensive care unit. J Ankara Univ Fac Med 62: 29-33.
6. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Comas J, Sakr Y, Reinhart K, EPIC II Group of Investigators (2009) International study of the prevalence and outcomes of infection in intensive care units. JAMA 302: 2323-2329.
7. Hynes-Gay P, Lalla P, Leo M, Merrill-Bell A, Nicholson M, Villaruel E (2002) Understanding sepsis: from SIRS to septic shock. Dynamics. Spring13:17-20, 22-4; quiz 25-6.
8. Bonten MJ (2012) Colonization pressure: a critical parameter in the epidemiology of antibiotic-resistant bacteria. Crit Care 16:142.
9. Schwaber MJ, Carmeli Y (2009) The effect of antimicrobial resistance on patient out comes: importance of proper evaluation of appropriate therapy. Crit Care 13:106.
10. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1-12.
11. Ziakas PD, Anagnostou T, Mylonakis E (2014) The prevalence and significance of mexitilin-resistant Staphylococcus aureus colonization at admission in the general ICU Setting: a meta-analysis of published studies. Crit Care Med 42:433-444.
12. Neidell MJ, Cohen B, Furuya Y, Hill J, Jeon CY, Glied S, Larson EL (2012) Costs of healthcare- and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms. Clin Infec Dis 55:807-815.
13. Safdar N, Maki DG (2002) The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococci, Gram-negative bacilli, Clostridium difficile and Candida. Ann Intern Med 136:834-844.
14. Ang H, Sun X (2018) Risk factors for multidrug-resistant Gram-negative bacteria infection in intensive care units: A meta-analysis. Int J Nurs Pract 24:e12644.
15. Paterson DL, Bonomo RA (2005) Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 18:657-86.
16. Marchaim D, Chopra T, Bhargava A, Bogan C, Dhar S, Hayakawa K, Pogue JM, Bheemreddy S, Blunden C, Shango M, Swan J, Lephart PR, Perez F, Bonomo RA, Kaye KS (2012) Recent exposure to antimicrobials and carbapenem-resistant Enterobacteriaceae: the role of antimicrobial stewardship. Infect Control Hosp Epidemiol 33:817-830.
17. Chow JK, Golan Y, Ruthazer R, Karchmer AW, Carmeli Y, Lichtenberg DA, Chawla V, Young JA, Hadley S (2008) Risk factors for albicans and non-albicans candidemia in the intensive careunit. Crit Care Med 36:1993-1998.
18. Kullberg BJ, Arendrup MC (2015) Invasive Candidiasis. N Engl J Med 373:1445-14456.

**Corresponding author**

Duygu Mert, MD
University of Health Sciences Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology. Mehmet Akif Ersoy mah., Vatan cad., No:91, 06300, Yenimahalle/Ankara, Turkey.
Tel: +90 5066486279
Fax: +90 3123466747
E-mail: drduyugumert@hotmail.com

**Conflict of interests:** No conflict of interests is declared.